This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third Opinion: Evaluating the potential of Nektar's Rezpegaldesleukin (IL-2 inhibitor) in patients with Alopecia Areata and Atopic Dermatitis

Ticker(s): NKTR

Who's the expert?

Institution: George Washington University

  • Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis.
  • Manages 50+ patients with Alopecia Areata and Atopic Dermatitis; Has extensive experience in the advanced management of atopic dermatitis, hand eczema, chronic itch, psoriasis, hidradenitis and many other chronic inflammatory skin disorders.
  • Research interests include drug development, clinical trial design, biomarkers, dermato-epidemiology, health services research, patient-reported outcomes, comorbidities and burden of itch and inflammatory skin disease and evidence-based dermatology. 

Interview Goal
This call will feature a discussion on the current treatment landscape for alopecia areata and atopic dermatitis along with the potential of Nektar's Rezpegaldesleukin.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.